Sagimet, NASH liver disease drug developer, sets terms for $75M IPO (Pending:SGMT)
Chunumunu Sagimet Biosciences (SGMT), which has been growing therapies for liver illnesses reminiscent of NASH, has ...
Read more
Copyright © 2023 Special Business Center.
Special Business Center is not responsible for the content of external sites.
Copyright © 2023 Special Business Center.
Special Business Center is not responsible for the content of external sites.